Clinical trials: Moderate to Severe Asthma
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Airway Inflammation and Disease Burden in Asthmatic Smokers
Aim : To compare, among patients with an uncontrolled moderate to severe asthma, the blood eosinophil levels of smokers and non-smokers.
- Trial name
- NCT02833727
- Testing
- Smoking
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Université de Montréal
Asthma
Effect of OPEP on Mucus Plugging and Airflow Obstruction in Patients with Moderate-to-severe Asthma
The goal of this randomized clinical trial is to evaluate the effect of daily AerobikaTM Oscillating Positive Expiratory Pressure (OPEP) device use on mucus plugging and airway function in adult patients with moderate-to-severe…
- Trial name
- AeroMUC (NCT06147453)
- Testing
- Aerobika OPEP device
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma.
- Trial name
- NCT06977581
- Testing
- PF-07275315
- Where
- 137 sites in United States, Argentina and 13 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Lung Disease
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.
- Trial name
- NCT00139152
- Testing
- Xolair
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Creighton University
Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps
Background: "Remission" is a primary therapeutic goal in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), though definitions vary regarding olfactory function.
- Trial name
- DREAM-NP (NCT07574294)
- Testing
- Not applicable- observational study, Dupilumab
- Where
- Italy
- Volunteers
- 205 people
- Sponsor
- Azienda Ulss 2 Marca Trevigiana
Asthma
GSK2190915 Moderate to Severe Asthma Study
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe…
- Trial name
- NCT00850642
- Testing
- GSK2190195 100mg
- Where
- 8 sites in Canada, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
This is a global Phase 2 study divided in two parts. Part A is a double-blind, randomized dose-range finding study in adults with moderate to severe asthma to confirm the dosing regimen of WIN378 that can be tested in future…
- Trial name
- Polaris (NCT07120503)
- Testing
- WIN378
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 600 people
- Sponsor
- Windward Bio
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Asthma Bronchiale
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.
- Trial name
- NCT00476073
- Testing
- FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
- Where
- United Kingdom
- Volunteers
- 228 people
- Sponsor
- Mundipharma Research Limited
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to…
- Trial name
- NCT00394121
- Testing
- Fluticasone propionate/formoterol fumarate
- Where
- 28 sites in Germany, Hungary and 3 more
- Volunteers
- 400 people
- Sponsor
- SkyePharma AG
Intrinsic Asthma, Allergic Asthma
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma.
- Conditions
- Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness
- Trial name
- BHR (NCT01144910)
- Testing
- methacholine challenge test
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Asthma
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
- Trial name
- NCT01070524
- Testing
- CHF 5188 pMDI, Budesonide extrafine pMDI, Seretide(r) Evohaler(r)
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Moderate Asthma Exacerbation, Severe Asthma Exacerbation
Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department
Acute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or…
- Trial name
- EOLE (NCT05691218)
- Testing
- Standard Nebulization, A - Vibrating mesh nebulization, B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Asthma
Asthma Exacerbation Study
Asthma is a clinical syndrome that is well recognized by health care practitioners, yet asthma pathogenesis still remains poorly understood.
- Trial name
- NCT00853411
- Testing
- prednisone
- Sponsor
- University of Pittsburgh
Asthma
Creation of Home-based Asthma Real-World Measures With Mobile Health Study
Four novel biologic therapies (benralizumab, dupilumab, mepolizumab, reslizumab) have been recently approved for moderate-to-severe, eosinophilic or oral steroid-dependent asthma.
- Trial name
- CHARM (NCT04462224)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Jewish Health
Asthma
A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
- Trial name
- NCT05155020
- Testing
- AK120
- Where
- 19 sites in China
- Volunteers
- 1 people
- Sponsor
- Akeso
Allergic Rhinitis, Asthma
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic…
- Trial name
- NCT00599027
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca